Fig. 1From: Uro-Vaxom® versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility studyConsolidated Standards of Reporting Trials (CONSORT) DiagramBack to article page